share_log

HC Wainwright & Co. Maintains Buy on Halozyme Therapeutics, Lowers Price Target to $60

Benzinga ·  Aug 15, 2023 07:13

HC Wainwright & Co. analyst Mitchell Kapoor maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and lowers the price target from $61 to $60.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment